Hyderabad: Bharat Biotech on 28 April announced that it was reducing the price of its COVID-19 vaccine, Covaxin, for the states from Rs. 600 to Rs. 400 per dose.
"Bharat Biotech is deeply concerned with the critical pandemic circumstances that India is facing at this time. Recognizing the enormous challenges to the public health care system, we have made Covaxin available to the state governments at a price of Rs. 400 per dose," it said in a statement.
On 24 April, Bharat Biotech had announced that Covaxin would be sold at Rs. 600 a shot to states and Rs. 1,200 to private hospitals, days ahead of the next phase of vaccinations from 1 May which will inoculate everyone above the age of 18. The pharma company has not disclosed what price it is charging the Central government for the vaccine. Earlier, it was charging Rs. 150 per dose.
Bharat Biotech will continue to sell Covaxin to private hospitals for Rs. 1,200.
"We wish to be transparent in our approach to pricing which was determined by internally-funded product development. Several operationally-intensive BSL-3 manufacturing facilities and clinical trials," Bharat Biotech said.
The pharma company also said that since last year, the Bharat Biotech team has been fearlessly handling live SARS-CoV-2 virus strains and tirelessly working round-the-clock while overcoming many challenges given the uncertainty of the pandemic.
"With the greater part of the organization's facilities and resources being diverted to COVID-19 vaccines, we continue to work towards offering superior COVID-19 vaccines and sincerely wish that this gesture enables our country towards a faster recovery," it added.